Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 266


Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.

Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F.

J Urol. 2018 Nov;200(5):956-966. doi: 10.1016/j.juro.2018.04.083. Epub 2018 May 3. Review.


Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth.

Mohamed AA, Xavier CP, Sukumar G, Tan SH, Ravindranath L, Seraj N, Kumar V, Sreenath T, McLeod DG, Petrovics G, Rosner IL, Srivastava M, Strovel J, Malhotra SV, LaRonde NA, Dobi A, Dalgard CL, Srivastava S.

Cancer Res. 2018 Jul 1;78(13):3659-3671. doi: 10.1158/0008-5472.CAN-17-2949. Epub 2018 Apr 30.


Legends in Urology.

McLeod DG.

Can J Urol. 2018 Apr;25(2):9221-9227. No abstract available.


Re: Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.

McLeod DG, Petrovics G.

Eur Urol. 2018 Feb;73(2):301-302. doi: 10.1016/j.eururo.2017.09.035. Epub 2017 Oct 14. No abstract available.


Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.

Cullen J, Young D, Chen Y, Degon M, Farrell J, Sedarsky J, Baptiste W, Rosen P, Tolstikov V, Kiebish M, Kagan J, Srivastava S, Kuo HC, Moncur JT, Rosner IL, Narain N, Akmaev V, Petrovics G, Dobi A, McLeod DG, Srivastava S, Sesterhenn IA.

Eur Urol Focus. 2018 Dec;4(6):818-824. doi: 10.1016/j.euf.2017.02.016. Epub 2017 Mar 11.


Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.

Mohamed AA, Tan SH, Xavier CP, Katta S, Huang W, Ravindranath L, Jamal M, Li H, Srivastava M, Srivatsan ES, Sreenath TL, McLeod DG, Srinivasan A, Petrovics G, Dobi A, Srivastava S.

Mol Cancer Res. 2017 Oct;15(10):1308-1317. doi: 10.1158/1541-7786.MCR-17-0058. Epub 2017 Jun 12.


Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.

Rastogi A, Ali A, Tan SH, Banerjee S, Chen Y, Cullen J, Xavier CP, Mohamed AA, Ravindranath L, Srivastav J, Young D, Sesterhenn IA, Kagan J, Srivastava S, McLeod DG, Rosner IL, Petrovics G, Dobi A, Srivastava S, Srinivasan A.

Genes Cancer. 2016 Nov;7(11-12):394-413. doi: 10.18632/genesandcancer.126.


Re: Inherited DNA-repair Gene Mutations in Men with Metastatic Prostate Cancer.

McLeod DG, Srivastava S.

Eur Urol. 2017 Apr;71(4):692. doi: 10.1016/j.eururo.2016.12.018. Epub 2017 Jan 6. No abstract available.


A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men.

Petrovics G, Li H, Stümpel T, Tan SH, Young D, Katta S, Li Q, Ying K, Klocke B, Ravindranath L, Kohaar I, Chen Y, Ribli D, Grote K, Zou H, Cheng J, Dalgard CL, Zhang S, Csabai I, Kagan J, Takeda D, Loda M, Srivastava S, Scherf M, Seifert M, Gaiser T, McLeod DG, Szallasi Z, Ebner R, Werner T, Sesterhenn IA, Freedman M, Dobi A, Srivastava S.

EBioMedicine. 2015 Oct 31;2(12):1957-64. doi: 10.1016/j.ebiom.2015.10.028. eCollection 2015 Dec.


Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.

Madan RA, Karzai FH, Ning YM, Adesunloye BA, Huang X, Harold N, Couvillon A, Chun G, Cordes L, Sissung T, Beedie SL, Dawson NA, Theoret MR, McLeod DG, Rosner I, Trepel JB, Lee MJ, Tomita Y, Lee S, Chen C, Steinberg SM, Arlen PM, Gulley JL, Figg WD, Dahut WL.

BJU Int. 2016 Oct;118(4):590-7. doi: 10.1111/bju.13412. Epub 2016 Feb 19.


Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods.

He J, Schepmoes AA, Shi T, Wu C, Fillmore TL, Gao Y, Smith RD, Qian WJ, Rodland KD, Liu T, Camp DG 2nd, Rastogi A, Tan SH, Yan W, Mohamed AA, Huang W, Banerjee S, Kagan J, Srivastava S, McLeod DG, Srivastava S, Petrovics G, Dobi A, Srinivasan A.

J Transl Med. 2015 Feb 12;13:54. doi: 10.1186/s12967-015-0418-z.


Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.

Li H, Mohamed AA, Sharad S, Umeda E, Song Y, Young D, Petrovics G, McLeod DG, Sesterhenn IA, Sreenath T, Dobi A, Srivastava S.

Oncotarget. 2015 Jun 20;6(17):15137-49.


Prostate cancer marker panel with single cell sensitivity in urine.

Nickens KP, Ali A, Scoggin T, Tan SH, Ravindranath L, McLeod DG, Dobi A, Tacha D, Sesterhenn IA, Srivastava S, Petrovics G.

Prostate. 2015 Jun 15;75(9):969-75. doi: 10.1002/pros.22981. Epub 2015 Mar 23.


A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.

Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, Ali A, Chen Y, Knezevic D, Maddala T, Lawrence HJ, Febbo PG, Srivastava S, Sesterhenn IA, McLeod DG.

Eur Urol. 2015 Jul;68(1):123-31. doi: 10.1016/j.eururo.2014.11.030. Epub 2014 Nov 29.


A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer.

Karzai FH, Apolo AB, Cao L, Madan RA, Adelberg DE, Parnes H, McLeod DG, Harold N, Peer C, Yu Y, Tomita Y, Lee MJ, Lee S, Trepel JB, Gulley JL, Figg WD, Dahut WL.

BJU Int. 2015 Oct;116(4):546-55. doi: 10.1111/bju.12986. Epub 2015 Jun 8.


Predominance of ERG-negative high-grade prostate cancers in African American men.

Farrell J, Young D, Chen Y, Cullen J, Rosner IL, Kagan J, Srivastava S, McLEOD DG, Sesterhenn IA, Srivastava S, Petrovics G.

Mol Clin Oncol. 2014 Nov;2(6):982-986. Epub 2014 Aug 7.


Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer.

Rastogi A, Tan SH, Mohamed AA, Chen Y, Hu Y, Petrovics G, Sreenath T, Kagan J, Srivastava S, McLeod DG, Sesterhenn IA, Srivastava S, Dobi A, Srinivasan A.

Genes Cancer. 2014 Jul;5(7-8):273-84.


ERG monoclonal antibody in the diagnosis and biological stratification of prostate cancer: delineation of minimal epitope, critical residues for binding, and molecular basis of specificity.

Rastogi A, Tan SH, Banerjee S, Sharad S, Kagan J, Srivastava S, McLeod DG, Srivastava S, Srinivasan A.

Monoclon Antib Immunodiagn Immunother. 2014 Aug;33(4):201-8. doi: 10.1089/mab.2014.0026.


Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer.

Metwalli AR, Rosner IL, Cullen J, Chen Y, Brand T, Brassell SA, Lesperance J, Porter C, Sterbis J, McLeod DG.

Urol Oncol. 2014 Aug;32(6):761-8. doi: 10.1016/j.urolonc.2014.03.024. Epub 2014 Jun 11.


Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer.

Sharad S, Ravindranath L, Haffner MC, Li H, Yan W, Sesterhenn IA, Chen Y, Ali A, Srinivasan A, McLeod DG, Yegnasubramanian S, Srivastava S, Dobi A, Petrovics G.

Epigenetics. 2014 Jun;9(6):918-27. doi: 10.4161/epi.28710. Epub 2014 Apr 2.

Supplemental Content

Loading ...
Support Center